PRESS RELEASE
G




Inventiva to Participate in Fireside Chat at the Canaccord
Genuity 45th Annual Growth Conference

Daix (France), New York City (New York, United States), August 11, 2025 – Inventiva (Euronext Paris and
NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the
development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”),
today announced that Jason Campagna, MD, PhD, President of R&D and Chief Medical Officer, and David
Nikodem, PhD, Vice President of US Operations will participate in a fireside chat at the Canaccord Genuity 45th
Annual Growth Conference. The conference is being held from August 12-14, 2025, at the InterContinental Hotel
in Boston, Massachusetts.

During the fireside chat, Drs. Campagna and Nikodem will highlight recent corporate updates, progress on
lanifibranor and the Phase III NATiV3 trial in MASH and discuss the Company’s broader R&D strategy and outlook.

Fireside chat details are as follows:
Date: Wednesday, August 13, 2025
Time: 10:30 am, Eastern Time


About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small
molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical
need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase
3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA,
ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA).
http://www.inventivapharma.com

Contacts

Inventiva ICR Healthcare ICR Healthcare
Pascaline Clerc Alexis Feinberg Patricia L. Bank
EVP, Strategy and Corporate Affairs Media Relations Investor Relations
media@inventivapharma.com inventivapr@icrhealthcare.com patti.bank@icrhealthcare.com
+1 202 499 8937 +1 203 939 2225 +1 415 513 1284




1